Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
What does it do?
Becton, Dickinson (BD) makes the medical gear that hospitals use every single day — think the needles that draw your blood, the IV lines that deliver medicine into your arm, and the machines that analyze lab samples. If you've ever been in a hospital and had blood taken or received a drip, there's a good chance BD made the equipment involved. They also make tools for drug companies to package and deliver injectable medicines. It's the kind of company you never hear about as a patient, but healthcare simply couldn't run without it.
BD sits at the center of global healthcare infrastructure — its products are consumables, meaning hospitals reorder them constantly rather than buying them once, which creates a reliable, recurring revenue stream. With an aging global population driving more hospital visits, surgeries, and chronic disease management, demand for BD's bread-and-butter supplies is structurally growing. The company is also pushing into higher-tech connected devices and diagnostics, trying to evolve beyond low-margin commodity supplies.
How does it make money?
BD makes money across five segments. Medical Essentials covers the basics — IV catheters, syringes, and needles — the high-volume, repeat-purchase products that anchor the business. Connected Care handles smarter infusion and medication delivery systems sold to hospitals. BioPharma Systems sells drug delivery components to pharmaceutical companies. Interventional covers surgical and vascular tools. Life Sciences focuses on lab equipment and diagnostics. Revenue grew from $20.2B to $21.8B in the latest year, a roughly 8% increase, with net income sitting at $1.7B.
Why do investors care?
The core investment idea is straightforward: BD sells products hospitals literally cannot operate without, giving it pricing power and steady demand regardless of economic cycles — people don't skip surgery because the economy slows. The growth story rests on two pillars: first, expanding in faster-growing emerging markets where healthcare infrastructure is still being built; second, shifting its product mix toward higher-value connected devices and diagnostics that command better margins. The company has also signaled plans to spin off its biosciences and diagnostic unit, which could unlock hidden value by letting each business trade on its own merits.
Deep Dive
MemberA full investor briefing on Becton, Dickinson and Company — history, leadership, risks, and outlook.